KLOW Peptide

KLOW Peptide Results in the Research Literature — Wound Healing and Tissue Repair Findings

In plain English

KLOW results in the literature are component results, not blend results. The four peptides in the KLOW stack have been studied separately; the combination has no controlled study. This page indexes the headline quantitative findings for each component, attributed to the source study. These are the data that give the blend its biological rationale — but they do not constitute evidence that the blend achieves these outcomes.

KLOW Results in the Research Literature

The wound re-epithelialization data for the TB-500 arm are the most quantitatively precise results in the KLOW record:

  • +42% re-epithelialization at four days (thymosin beta-4 vs saline, rat full-thickness wound model) [1]
  • +61% re-epithelialization at seven days [1]
  • +11% wound contraction by day seven [1]
  • 10 pg active concentration in keratinocyte migration assays (two- to three-fold migration increase) [1]
  • Raised collagen deposition and angiogenesis at both time points [1]

For BPC-157:

  • Fully transected rat Achilles tendon: improved load-to-failure biomechanics, functional gait scores, collagen organization and macroscopic tendon integrity versus untreated controls at 10 microg, 10 ng and 10 pg/rat/day [2]
  • In vitro tendocyte outgrowth stimulated at all three doses [2]
  • First human IV pilot (n=2): 10 and 20 mg IV well tolerated, no adverse events, no biomarker changes [6]

For GHK-Cu:

  • Topical GHK-Cu: collagen production increased in 70% of treated women vs 50% for vitamin C and 40% for retinoic acid [4]
  • Plasma GHK: ~200 ng/mL at age 20, ~80 ng/mL at age 60 [4]
  • Gene-modulation bioinformatics: ~31.2% of human protein-coding genes modulated at 50% change threshold; strongest signals on ECM, DNA repair and ubiquitin-proteasome [5]
  • Hair-count trial (n=45 men): +52.6 hairs (100 mg/mL) and +71.5 hairs (50 mg/mL) vs +9.6 for placebo over six months (p<0.05) [11]

For KPV:

  • Nanomolar KPV (10 nM): NF-kappaB and MAPK activation reduced, TNF-alpha / IL-6 / IL-1beta / IL-8 secretion reduced in intestinal epithelial cells and T cells in vitro [3]
  • Oral KPV: reduced DSS- and TNBS-induced colitis severity in mice [3]

For full context on each result see KLOW research.

What the blend gap means for these results

Every number above is a single-component result. None is a blend result. The KLOW peptide blend itself has zero controlled studies — no phase, no species, no model. The combination may amplify, duplicate, interfere with or have no interaction with each component's pathway; the literature does not say. These klow results are the closest proxy available, and they are component proxies.

Recent literature (2024-2026)

Three recent publications extend the BPC-157 arm's record:

2026: Tracheocutaneous fistula resolved by BPC-157 therapy through NO-system mediation (rat model) — the nitric-oxide pathway again [14].

2025: BPC-157 reduced liver, kidney and lung injury secondary to acute pancreatitis in rats — multi-organ protection in a systemic inflammatory model [13].

2025: A literature and patent review surveyed BPC-157's multifunctional record, covering IBD, gastric ulcer, wound healing, tendon, bone, muscle, CNS and cardiovascular models [15].

2026: A Sports Medicine review evaluated approved and unapproved peptide therapies for musculoskeletal injuries; TB-500 / thymosin beta-4 and BPC-157 were among the compounds reviewed. Conclusion: favorable animal-model results, scarce human safety data, no regulatory approval [7].